Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study

References

• Roehrborn CG, Boyle P; ARIA3001 ARIA3002 and ARIA3003 Study Investigators, et al. Efficacy and safety of a dual inhibitor of 5-Alpha-Reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Lemay A, Zwicker H, et al. Effect of finasteride, a 5alpha-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab 1992;75:84–8
   Google Scholar
• Roehrborn CG, Nickel JC, Andriole GL, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011;78:641–6
   PubMed Web of Science ®Google Scholar
• Rittmaster R, Hahn RG, Ray P, et al. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008;72:808–12
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Baltimore Longitudinal Study of Aging: longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724–31
   PubMed Web of Science ®Google Scholar
• Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427–48
   PubMedGoogle Scholar
• Comhaire FH. Andropause hormone replacement therapy in the ageing male. Eur Urol 2000;38:655–62
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53–8
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010;13:242–6
   PubMed Web of Science ®Google Scholar
• Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996;3:261–6
   PubMedGoogle Scholar
• Namiki M, Akaza H, Shimazui T; Working Committee on Clinical Practice Guidelines for Late-onset Hypogonadism; Japanese Urological Association/Japanese Society for Study of Aging Male, et al. Working Committee on Clinical Practice Guidelines for Late-onset Hypogonadism; Japanese Urological Association/Japanese Society for Study of Aging Male. Clinical practice manual for late-onset hypogonadism syndrome. Int J Urol 2008;15:377–88
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 2005;8:59–74
   PubMedGoogle Scholar
• Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009;16:745–50
   PubMed Web of Science ®Google Scholar
• Rittmaster R, Hahn RG, Ray P, et al. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008;72:808–12
   PubMed Web of Science ®Google Scholar
• Hong SK, Min GE, Ha SB, et al. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int 2010;105:970–4
   PubMed Web of Science ®Google Scholar
• McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97:23–8
   PubMed Web of Science ®Google Scholar
• Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011;52:657–63
   PubMedGoogle Scholar
• Chamness SL, Ricker DD, Crone JK, et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 1995;63:1101–7
   PubMed Web of Science ®Google Scholar
• Mitterberger M, Pallwein L, Gradl J, et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 2007;99:831–5
   PubMedGoogle Scholar
• McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838–45
   PubMed Web of Science ®Google Scholar
• Azadzoi KM, Tarcan T, Kozlowski R, et al. Overactivity and structural changes in the chronically ischemic bladder. J Urol 1999;162:1768–78
   PubMed Web of Science ®Google Scholar
• Okutsu H, Matsumoto S, Hanai T, et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75:235–40
   PubMedGoogle Scholar
• Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 2008;179:2333–8
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–91
   PubMed Web of Science ®Google Scholar
• Matsumoto AM, Tenover L, McClung M; Pless Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002;167:2105–8
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Cheetham TC, Haque R, et al. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA 2008;300:1660–4
   PubMed Web of Science ®Google Scholar
• Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012;307:931–9
   PubMed Web of Science ®Google Scholar
• Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A BiolSci Med Sci 2001;56:M266–72
   PubMed Web of Science ®Google Scholar
• van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000;85:3276–82
   PubMed Web of Science ®Google Scholar
• Page ST, Hirano L, Gilchriest J, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011;186:191–7
   PubMed Web of Science ®Google Scholar